

April 20, 2021

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Subject: Launch of Benralizumab 30mg/mL solution for injection (Fasenra™)

We refer to our earlier communication dated December 20, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™)

With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has launched Fasenra™ in India on April 20, 2021.

Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.

We request you to kindly take the above on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

Pratap Rudra

Company Secretary & Legal Counsel